Medroxyprogesterone acetate injectable suspension recalled for lack of sterility assurance
Sun Pharmaceutical is recalling medroxyprogesterone acetate injectable suspension (150 mg/mL) nationwide due to lack of assurance of sterility. Affected lots contain vials with expiration dates from December 2022 through September 2023.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of an injectable medication with lack of sterility assurance. While no illnesses or injuries have been reported, the hazard presents significant risk of harm—potential bacterial contamination could cause serious infections when administered to patients.
Plain-English summary
Sun Pharmaceutical Industries Inc. is recalling medroxyprogesterone acetate injectable suspension, USP, 150 mg/mL, 1 mL single-dose vials (NDC 16714-981-01), manufactured for Northstart Rx LLC. Approximately 180,813 syringes have been distributed nationwide.
The recall was initiated due to lack of assurance of sterility in the affected lots. Injectable medications must maintain sterile conditions to prevent bacterial contamination, which could lead to serious infections when administered.
Affected lot numbers with expiration dates are: HAC2075A (06/2023), HAC2076A (07/2023), HAC2077A (08/2023), HAC2078A (08/2023), HAC3803A (09/2023), HAC0551A (02/2023), HAC0562A (03/2023), HAC1183A (03/2023), HAC1807A (06/2023), JKX6017A (12/2022), JKX6018A (12/2022), HAC0163A (01/2023), HAC1184A (04/2023), and HAC0162A (12/2022). Healthcare providers and patients with this medication should contact their healthcare provider and should not use affected vials.
The recalled product
- Product
- medroxyPROGESTERone Acetate Injectable Suspension, USP, 1 mL Single-Dose Vial, 150 mg/mL, Rx only, Manufactured for: Northstart Rx LLC, Memphis, TN, 38141, Manufactured by: Sun Pharmaceutical Industries Ltd., Halol Baroda Highway, Halol-389 350, Gujarat India , NDC 16714-981-01
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Injectable Contraceptive
- Hazard
- sterility-assurance
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: HAC2075A
- Exp 06/2023
- HAC2076A
- Exp 07/2023
- HAC2077A
- HAC2078A
- Exp 08/2023
- HAC3803A
- Exp 09/2023
- HAC0551A
- Exp 02/2023
- HAC0562A
- HAC1183A
- Exp 03/2023
- HAC1807A
- JKX6017A
- JKX6018A Exp 12/2022
- HAC0163A
- Exp 01/2023
- HAC1184A
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27